Company
Brahms
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
2
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Brahms, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Brahms.
Latest FDA decisions
- B·R·A·H·M·S sFlt-1/ PlGF KRYPTOR Test SystemNew device typeBreakthroughDe Novo
DEN220027 · Decided May 18, 2023 · 381 days after receipt
Device type: Prognostic Test For Development Or Progression Of Preeclampsia (QWH) · Laboratory Medicine & Pathology
K171338 · Decided May 31, 2017 · 23 days after receipt
Device type: Procalcitonin Assay (PRI) · Laboratory Medicine & Pathology
- B.R.A.H.M.S PCT sensitive KRYPTORNew device typeDe Novo
DEN150009 · Decided Feb 20, 2016 · 353 days after receipt
Device type: Device To Detect And Measure Procalcitonin (Pct) In Human Clinical Specimens (PMT) · Laboratory Medicine & Pathology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Risk Stratification Using Midregional Proadrenomedullin in the EDPivotal-lookingCompleted
NCT05108883 · 463 participants · Start Oct 14, 2021 · Primary completion Nov 7, 2023
Device: MR-proADM KRYPTOR · For: Patients Presenting With Suspicion of Infection to the ED
Sites: Paris, France; Roma, Italy; Udine, Italy · 9 sites in all
- Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of InfectionTerminated
NCT00407147 · 11 participants · Start Jul 2008 · Primary completion Jun 2009
Device: Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor · For: Infection; Bacterial Infection; Sepsis
Sites: St Louis, Missouri; Camden, New Jersey; Providence, Rhode Island
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1795-2026 · Started Mar 12, 2026 · Posted by FDA Apr 8, 2026
Reason given: Customers have observed quality control values out of range at the lowest quality control level (QC Level 1) for the PIGF assay which require troubleshooting steps to resolve. If Quality Controls are not performed according to the Instructions for Use, the underestimation of QC1 may go undetected and could contribute...
Cause as FDA categorized it: Under Investigation by firm · Device type: Prognostic Test For Development Or Progression Of Preeclampsia (QWH)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.